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In Nuclear disasters whether they happen in war or occur 
accidentally the results are always very devastating.  
Following a Nuclear disaster all doctors, along with 
haematologists  would be called out to participate. It is 
imperative to develop  treatment guidelines for post 
radiation emergencies. Though such guidelines are available 
all around the world we outline the current plans for event 
response including catastrophic events that would require 
extensive support. 
The threat of possible nuclear disaster whether 
due to detonation of a nuclear device or due to 
accidents in handling of the radioactive materials 
requires that we develop and implement a plan of 
response.1  More than 400 radiologic accidents have 
occurred since 1944, resulting in more than 3000 
significant exposures. Approximately 10 million 
“sealed sources” of radioactive material (e.g., cesium-
137, cobalt-60) are used for medical, industrial, 
agricultural, and research purposes worldwide. More 
than 600 of these were lost or stolen since 1995 and less 
than half were eventually recovered.  
The haemopoietic system is the most rapidly 
dividing tissue of the body and as such the most 
vulnerable of all and most radiosensitive. Exposure of 
the haemopoietic stem cell as well as the progenitor 
cells results in their exponential death. The 
haemopoietic progenitor cells cannot survive a dose of 
>2-3 Gray (Gy).It results in haematological disaster in 
subsequent days including lymphopenia, bone 
marrow atrophy ,pancytopenia and bleeding which all 
contribute to its lethality. 2 
Models suggest that, if a device similar to the 
bomb detonated over Hiroshima struck a city such as 
Karachi up to 175 000 victims would require intensive 
medical care and 300 000 would require management 
for myelosuppression. 3 
Establishing National Haematology Radiation 
Injury Treatment Organization  
It is purposed that a Pakistan Haematology 
Radiation Injury Treatment Organization be 
established on the lines of Radiation Injury Treatment 
network (RITN) in the United States which was raised 
in the year 2001.4 
The scope of Pakistan Haematology Radiation 
Injury Treatment Organization (PHRITO) would be as 
follows: 5 
1. To develop treatment guidelines for 
managing haematologic toxicity among victims of 
radiation exposure 
2. To educate healthcare professionals about 
pertinent aspects of radiation exposure management 
3. To coordinate situation response after a 
radiation event 
4. To provide comprehensive evaluation and 
treatment for victims at participating HSCT centers. 
What a Haematologist needs to know in case of 
Radiation Event  
1. Discovering an Event: 
Several types of events can result in radiation 
exposure. A Haematologist must posses a basic 
knowledge about the spectrum of potential events 
involving radioactive material.  
 
Table 1   Algorithm for discovering 
Radiation event 6 
 
Journal of Rawalpindi Medical College (JRMC); 2009;13(2):98-102 
 99 
Several types of events could result in 
radiation exposure. Intentional events can involve 
radiologic exposure devices (REDs), radiologic 
dispersion devices (RDDs), and improvised nuclear 
devices (INDs). An RED is a radioactive source placed 
surreptitiously in a public space or other location. 7  
2. Triage after a radiation event 
Healthcare organizations have prepared their 
responses to radiation events for triage, transportation, 
and treatment of victims after an IND.The triage 
comprises four basic steps.  
First, Life threatening injuries must be dealt at once. 
The patients should be stabilized and shifted to a 
Medical facility and it should be presumed that the 
patients are contaminated. 
Second, Preliminary decontamination be performed. 
Third, Triage for Adults (START) and Children 
(JumpSTART) is started. Initial samples should include 
CBC, Blood chemistry and a sample for cytogenetics if 
required later. 8 
 Coloured tags are assigned to individual 
patients sorted out according to the severity of injury. 
 
 
Fig 1: Organization of triage centers 
Triage centers are located in concentric rings 
around the affected area, providing initial stabilization 
and decontamination (RTR1-RTR3), more extensive 
Medical Care (MC), and rapid screening of unexposed 
or minimally exposed individuals at Assembly Centers 
(AC). Patients who require further care are evacuated 
to referral centers in unaffected regions (fig 1). 9 
A conceptual model for triage, transportation, 
and treatment of victims after an IND, the RTR system 
(Radiation Triage, Treatment and Transportation) has 
been developed. Briefly, the initial triage and patient 
decontamination will occur at RTR sites, whose 
location and resources will be determined by incident 
commanders. RTR1 are near the blast andRTR2 are 
near the plume, both within areas of residual 
radiation. In contrast, RTR3 will be located outside the 
region with significant residual radiation. Based on 
previous radiation accidents, the number of 
unirradiated persons who seek medical attention after 
an event could dwarf the number exposed. For 
example, when scavengers in Goiania, Brazil, procured 
an improperly secured caesium source resulting in 28 
cases of radiation sickness, more than 112 000 people 
presented for screening at the nearby Olympic 
stadium.Victims requiring further care may be 
transferred to Medical Care (MC) sites located outside 
of the disaster zone. 10  
I. Role of Haematologist  in Acute Radiation Injury 
Acute radiation syndrome (ARS) can affect 
virtually any organ but primarily manifests as injury 
to rapidly dividing tissues. The severity of the ARS 
varies accordingly with the radiation dose .The clinical 
course of ARS generally includes a prodromal phase, 
followed by a period of apparent remission, manifest 
illness and ultimate recovery or death.11 
The haematopoietic syndrome develops 
between the doses of 3-8 Gy.Low dose exposure of<2 
Gy produces cytopenias but does not cause significant 
bone marrow damage. Peripheral blood lymphopenia 
develops within 6-24 hours. Radiation induces 
apoptosis and alters recirculation of lymphocytes. 
Based on the counts of peripheral blood lymhocytes, 
granulocytes, platelet count and blood loss, the 
haemopoietic response to radiation can be divided in 
different groups 
Role of Biodosimetery 
Treating Haematologists will be required to 
calculate radiation dose using the information they 
have. Forms of biological dosimetery include 
lymphocyte depletion kinetics, interphase aberrations 
induced by okadaic acid and p34cde2 /Cyclin B kinase 
and electron spin resonance of dental enamel.  
Monitoring for a decrease in absolute 
lymphocyte count has been found to be a reliable and 
practical method to assess soon after radiation 
exposure.Andrews et al have developed lymphocyte 
depletion kinetic curves which predict pattern of early 
lymphocyte response in relation to dose. Whenever 
possible in cooperation of data from three key 
elements, time to onset of vomiting, lymphocyte 
depletion kinetics and chromosome aberrations are 
required for assessment  of prognosis and selection of 
therapy. Patterns of lymphocyte response define 
stages stretching from normal to lethal.12 
The frequency of chromosomal aberrations in 
lymphocytes correlate well with the radiation dose. 
The formation of dicentrics involves an interchange 
between two separate chromosomes (fig 2). Ring 
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formation involves a break in the arm of a single 
chromosome followed with the rejoining to form a 
ring and a fragment.  
Chromosomal aberrations have become the 
gold standard in dosimetery.Their detection is 
facilitated by the application of hybridization probes 




Fig 2: Dicentric chromosomes after nuclear injury 
 
II. Management of Haematological Complications 
Cytopenias and Growth Factors 
Post radiation exposure cytopenias develop 
after 6-24 hours. Lymphocyte count is first to fall. 
There is a major decrease in the count of helper T cells. 
Irradiation to the bone marrow stem cells and the 
progenitor cells results in exponential 
death.Mitotically active haemopoietic cells are unable 
to divide after a dose of >2-3 Gy which leads to a 
haematological crises in the coming weeks. The result 
is lymphopenia, bone marrow atrophy pancytopenia 
and its attendant sequele: infection, bleeding and poor 
wound healing which contribute to its lethality. 
Sometimes pockets of radiation resistant stem cells are 
left behind. These stem cells play an important role in 
the recovery of the haematopoiesis after radiation dose 
exposure as high as >6 Gy. 13,14 
Haemopoietic colony stimulating factors like 
G-CSF, GM-CSF and PEG-G-CSF have shown to be 
effective in radiation induced bone marrow 
aplasia.Their enhancement of neutrophil recovery and 
most importantly their survival benefit as observed in 
carefully conducted clinical trials has shown them to 
be effective in patients of post radiation marrow 
aplasia. 
 
Fig 3: White blood cells count post radiation accident 
 
 A number of studies examining the role of G-
CSF,GM-CSF, pegylated G-CSF, and a chimeric 
molecule in an irradiated rhesus macaque’s model 
demonstrated significant neutrophil enhancement 
when these agents were employed on day 1 post 
exposure and continued for 14-21 consecutive days.15 
Use of blood products:  
High-dose whole body radiation exposure 
induces haematopoietic cytopenias potentially 
requiring transfusion of blood products. Cytopenias 
requiring transfusion occur typically 2 to 4 weeks after 
high-dose radiation exposure, although time to nadir 
varies by patient, exposure dose, and dose rate. Blood 
loss requiring transfusion may also result from trauma 
associated with the radiation incident and 
gastrointestinal losses from a variety of causes. 
Cellular blood products that will be transfused to 
radiation victims should  be, preferably, leucodepleted 
and/or irradiated, most importantly to prevent post 
transfusion graft versus host disease (PT-GVHD) 
 Avoid transfusions from first-degree relatives 
whenever possible because it increases the risk of PT-
GVHD. If no other option is available, this blood must 
be irradiated. Transfusion of fresh blood especially 
that stored for fewer than 3 days should be avoided 
whenever possible, except for platelet concentrates.  
The fresher the blood, the higher the risk of 
PT-GVHD, especially with blood used within 3 days 
after donation. Typical PT-GVHD presents with fever, 
generalized erythema 1 or 2 weeks after transfusion, 
followed by liver dysfunction, diarrhoea, and bone 
marrow failure with pancytopenia. Most patients die 
of multi-organ failure within 1 month of transfusion. 
PT-GVHD occurs at a higher rate in patients with no 
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history of blood transfusions and in patients who 
receive blood from relatives. 16 
Leukocyte reduction by filtration is not 
sufficient to prevent PT-GVHD, but it is recommended 
because it diminishes the febrile non-hemolytic 
reactions,immunosuppressive effects of blood 
transfusions platelet alloimmunization and  
cytomegalovirus infection . Blood and blood product 
irradiation will prevent PT-GVHD.  Both irradiation 
and leukocyte reduction are recommended when these 
are available.  
Platelet transfusion guidelines  
The benefits of pooled platelets or single 
donor platelets are similar; the two products can be 
used interchangeably. Single donor platelets from 
selected donors are preferred when histocompatible 
platelet transfusions (i.e., HLA-A and HLA-B antigen 
matched) are needed. 17 
Granulocyte transfusion guidelines 
Granulocyte transfusions should be 
considered for severely neutropenic patients (ANC 
<200/uL) when infection persists despite optimal 
antimicrobial and supportive therapy.  
Daily transfusions for a period of several days 
to weeks are guided by 24-hour WBC determinations 
and clinical response. Prophylactic transfusions have 
not been shown to reduce morbidity or mortality. 18 
III. Supportive Care 
For those who experience significant 
neutropenia (ANC < 500/μL) broad spectrum 
prophylactic antimicrobials should be employed as the 
neutropenic duration is likely to be prolonged. 
Prophylaxis should include a fluroquinolone (FQs) 
with streptococcal coverage (with penicillin or 
amoxicillin if not inherently covered by the FQ), as an 
antiviral agent if the patient is herpes simplex virus 
(HSV) positive, and an antifungal agent.  Studies in 
irradiated mice have demonstrated that the gut flora 
also undergoes a dose-related reduction within  the 
first 4 days post-radiation. This  is followed by a 
relative increase of Enterobacteriaceae  compared to 
anaerobic bacteria by the 12th day.  Fatal bacteraemia 
may then result from the bacterial translocation of 
these organisms. 19  
During the intense periods of 
immunosuppression, these patients are at high risk for 
HSV reactivation, which may be confused with 
radiation stomatitis and may complicate its 
management. can mimic or add to the severity of 
mucosal injury. Therapy of patients with neutropenia 
and infection should be guided by the 
recommendations of the Infectious Diseases Society of 
America (IDSA) and should take into consideration 
other foci of infection such as mucosal or integument 
injury.20 
Potassium Iodide 
Owing to their short half-lives, radionuclides 
are unlikely to be components of an RDD or “dirty 
bomb.” Therefore,  iodine prophylaxis is not indicated. 
Nevertheless, for an incident involving a nuclear 
power plant or an IND, it is probable that radioiodine 
will be released. Early prophylaxis is indicated in the 
latter situation. The thyroid is a radiosensitive organ at 
risk. Exposure to radioiodine can result in thyroid 
cancer, a delayed consequence, which may be more 
aggressive than de novo forms. Exposure could begin 
immediately if the released plume is near ground 
level. The main route of radioiodine exposure is 
inhalation in those in the near field and via ingestion 
of contaminated food and drink (particularly milk) for 
those further away (far field). Exposure via the latter 
route could last longer, cover a larger area, and affect a 
larger population. Thyroid blocking with potassium 
iodide (KI) affords protection when radioisotopes of 
iodine are components of the exposure. Oral 
administration of KI should be given as soon as 
possible after exposure (within 6 hours). Caution 
should be taken with those individuals who are 
allergic to iodine because severe reactions have been 
reported. KI should be dosed daily, until the exposure 
risk no longer exists. 21 
Role for stem cell transplantation 
Some victims of a large-scale event may 
receive sufficient doses of radiation to cause 
irreversible myeloablation. These patients will 
commonly have multi-organ damage. What remains 
unclear is whether allogenic HSCT can be a life-
sustaining measure in this setting. To date, 31 patients 
have undergone allogenic HSCT after accidental 
radiation exposure. Median survival after 
transplantation for these patients is approximately 1 
month. Only 4 patients survived 1 year reconstituted 
autologous haematopoiesis, raising the question 
whether the HSCT provided any benefit. 22 
Particularly troubling was the contribution of 
graft-versus-host disease to mortality in more than 
20% of patients. In many regards, patients with 
myeloablation from radiation exposure are similar to 
those with aplastic anaemia. A reduced intensity 
conditioning regimen for severe aplastic anaemia 
(where immunosuppression but not myeloablation is 
required) is being tested in the Blood and Marrow 
Transplant Clinical Trials Network (BMT CTN 
Protocol 0301). 
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The complex nature of radiation injury is such 
that no single drug provides benefit in all 
circumstances and against all aspects of radiation 
injury. Antioxidants and radioprotectants are 
presumably most effective if present at the time of 
irradiation, whereas therapeutics such as growth 
factors may target one or more but not all affected 
organ systems. For this reason, many experts think 
that combination therapy will be required to produce 
substantial improvements in outcomes.22 
 
Conclusion 
The widespread availability of radioactive 
material has made future exposure events, accidental 
or intentional, more likely . Haematologists, 
oncologists, and HSCT physicians are uniquely suited 
to care for victims of radiation exposure, creating a 
collective responsibility to prepare for a variety of 
contingencies. 
Government of Pakistan should establish 
Haematology Radiation Injury Treatment 
Organization (PHRITO) .The Organization should be 
involved in the planning to deal with Radiation 
injuries. Although the logistical difficulties inherent to 
any large-scale response are enormous, the potential 
for lifesaving measures is equally grand. PHRITO 
should standardize approaches to Biodosimetery, 
evaluation, and treatment. The protocols should be 
available for review, comment, and further 
development. PHRITO should focus on streamlining 
these processes, providing training to medical 
practitioners around the country, and validating 
medical countermeasures to reduce the morbidity and 
mortality of radiation exposure. 
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